Lenzilumab (KB 003) is a humanized monoclonal antibody specifically designed to neutralize colony-stimulating factor 2 (CSF2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody is utilized in research focused on COVID-19 and myelomonocytic leukemias, including chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Its targeted action against CSF2/GM-CSF makes it a valuable tool for understanding and potentially modulating inflammatory and immune responses in these disease states.
Lenzilumab (KB 003) is a humanized monoclonal antibody specifically designed to neutralize colony-stimulating factor 2 (CSF2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody is utilized in research focused on COVID-19 and myelomonocytic leukemias, including chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Its targeted action against CSF2/GM-CSF makes it a valuable tool for understanding and potentially modulating inflammatory and immune responses in these disease states.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
